Ciltyri Approval Status

  • FDA approved: No
  • Brand name: Ciltyri
  • Generic name: eplivanserin
  • Company: Sanofi-aventis
  • Treatment for: Insomnia

Ciltyri (eplivanserin) is a serotonin type 2 A receptor antagonist under review as a potential treatment for patients with chronic insomnia characterized by difficulties with sleep maintenance.

FDA Approval Status for Ciltyri

DateArticle
Sep 17, 2009Sanofi-Aventis Receives Complete Response Letter from the FDA for eplivanserin (Ciltyri) Submission

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web2)